Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increased cyclin E level in retinoblastoma cells during programmed cell death

M Lauricella1, M Giuliano, S Emanuele

  • 1Institute of Biological Chemistry, University of Palermo, Policlinico, Italy.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|January 5, 1999
PubMed
Summary

Topoisomerase inhibitors like camptothecin increase cyclin E levels in Y79 cells, triggering programmed cell death (PCD). This suggests cyclin E plays a role in the final stages of PCD induced by DNA-damaging agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis.

ESMO open·2026
Same author

[Expression of Concern] Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.

International journal of oncology·2026
Same author

Ghost-mode filtered fluctuating lattice Boltzmann method.

The Journal of chemical physics·2026
Same author

HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy.

NPJ breast cancer·2025
Same author

Regularized fluctuating lattice Boltzmann model.

The Journal of chemical physics·2025
Same author

RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer.

ESMO open·2025

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Topoisomerase inhibitors are crucial in cancer therapy.
  • Programmed cell death (PCD) is a key mechanism targeted by cancer drugs.
  • Y79 cells are a relevant model for studying drug-induced cell death.

Purpose of the Study:

  • To investigate the role of cyclin E in programmed cell death (PCD) induced by topoisomerase inhibitors in Y79 cells.
  • To determine if DNA damage is a prerequisite for cyclin E induction during PCD.

Main Methods:

  • Treatment of Y79 cells with various topoisomerase inhibitors (camptothecin, etoposide, amsacrine) and other PCD inducers.
  • Dose-dependent analysis of cyclin E levels.
  • Assessment of programmed cell death (PCD) markers.

Related Experiment Videos

  • Inhibition of macromolecular synthesis to study the mechanism.

    • Main Results:

    • Camptothecin, etoposide, and amsacrine significantly increased cyclin E levels in a dose-dependent manner.
    • Camptothecin demonstrated the highest efficacy in inducing cyclin E.
    • Other PCD inducers that do not damage DNA did not affect cyclin E levels.
    • The observed increase in cyclin E was dependent on macromolecular synthesis and occurred after a lag phase, correlating with PCD progression.

    Conclusions:

    • Topoisomerase inhibitors induce programmed cell death (PCD) in Y79 cells with a concurrent increase in cyclin E.
    • Cyclin E appears to be involved in the terminal stages of PCD triggered by topoisomerase inhibitors.
    • DNA damage is likely a critical factor for cyclin E induction in this context.